On October 17, 2006, the FDA approved Merck's Januvia™ for type 2 diabetes.
Januvia (sitagliptin) is an incretin enhancer. For a brief primer on how these drugs work, visit our post:
New Diabetes Drugs on the Horizon: Incretin Enhancers
Merck states the recommended dose as 100 mg/day. The 100 mg tablets will be available in pharmacies in the near future. Price: $4.86/tablet.
For FDA's press release:
FDA Approves New Treatment for Diabetes
For Merck's press release:
FDA Approves Once-Daily JANUVIA™, the First and Only DPP-4 Inhibitor Available in the United States for Type 2 Diabetes
For Januvia's site: